Monocyte Chemoattractant Protein-1/CC Chemokine Ligand 2 Controls Microtubule-Driven Biogenesis and Leukotriene B₄-Synthesizing Function of Macrophage Lipid Bodies Elicited by Innate Immune Response


J Immunol 2007; 179:8500-8508; doi: 10.4049/jimmunol.179.12.8500
http://www.jimmunol.org/content/179/12/8500

References
This article cites 45 articles, 22 of which you can access for free at:
http://www.jimmunol.org/content/179/12/8500.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Lipid bodies (also known as lipid droplets) are recognized as dynamic organelles with key roles in regulating storage and turnover of lipids in different cells and organisms. Beyond their function on lipid homeostasis, recent studies have placed lipid bodies as multifunctional organelles with roles in cell signaling, intracellular trafficking, and cell activation (1–3). Biogenesis of lipid bodies is a biological process that has been intensively studied over the past few years. The contemporary view of lipid body biogenesis establishes lipid bodies as endoplasmic reticulum (ER) \(^3\)-derived organelles. Two main models have been proposed: 1) formation of a neutral lipid mass synthesized by ER enzymes that is deposited in a hydrophobic domain between the two leaflets of the ER membrane, followed by budding off of this lipid structure into the cytoplasm that ends up surrounded by a half-unit membrane of phospholipids directly derived from the cytoplasmic leaflet of the ER (4); 2) formation of lipid bodies by incorporation of multiple loops of ER membranous domains, with accumulation of neutral lipids among the membranes within lipid bodies (5). In addition, proteins of the PAT family, named after perilipin, adipose differentiation-related protein and 5-lipoxygenase. Therefore, infection-elicited MCP-1, besides its known CCR2-driven chemotactic function, appears as a key activator of lipid body biogenesis in infection-driven inflammatory disorders and we described the cellular mechanisms and signaling pathways involved in the ability of MCP-1 to regulate the biogenesis and leukotriene \(\text{LTB}_4\) synthetic function of lipid bodies. In vivo assays in MCP-1 \(^{-/-}\) mice revealed that endogenous MCP-1 produced during polymicrobial infection or LPS-driven inflammatory responses has a critical role on the activation of lipid body-assembling machinery, as well as on empowering enzymatically these newly formed lipid bodies with \(\text{LTB}_4\) synthetic function within macrophages. MCP-1 triggered directly the rapid biogenesis of distinctive \(\text{LTB}_4\)-synthesizing lipid bodies via CCR2-driven ERK- and PI3K-dependent intracellular signaling in in vitro-stimulated macrophages. Disturbance of microtubule organization by microtubule-active drugs demonstrated that MCP-1-induced lipid body biogenesis also signals through a pathway dependent on microtubular dynamics. Besides biogenic process, microtubules control \(\text{LTB}_4\)-synthesizing function of MCP-1-elicited lipid bodies, in part by regulating the compartmentalization of key proteins, as adipose differentiation-related protein and 5-lipoxygenase. Therefore, infection-elicited MCP-1, besides its known CCR2-driven chemotactic function, appears as a key activator of lipid body biogenic and functional machineries, signaling through a microtubule-dependent manner. The Journal of Immunology, 2007, 179: 8500–8508.

Received for publication July 5, 2007. Accepted for publication October 5, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported by Howard Hughes Medical Institute (to P.T.B.), PRONEX-MCT, Conselho Nacional de Pesquisa (Brazil), and Fundação de Amparo à Pesquisa do Rio de Janeiro.

Address correspondence and reprint requests to Dr. Patricia T. Bozza, Laboratório de Imunofarmacologia, Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brazil 21045-900. E-mail address: pbozza@ioc.fiocruz.br or Dr. Christianne Bandeira-Melo, Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil 21941-902. E-mail address: cbmelo@biof.ufc.br

www.jimmunol.org

Abbreviations used in this paper: ER, endoplasmic reticulum; ADRP, adipose differentiation related protein; LDL, low-density lipoprotein; oxLDL, oxidized LDL; 5-LO, 5-lipoxygenase; \(\text{LTB}_4\), leukotriene \(\text{B}_4\); CLP, cecum ligation and puncture; EDAC, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/8200
Moreover, newly formed leukocyte lipid bodies have been implicated as key organelles in regulated arachidonate-derived inflammatory mediator synthesis with roles in immunity and inflammation. The detailed molecular mechanisms controlling the inducible lipid body biogenic process within leukocytes remains largely unclear (reviewed in Refs. 3 and 8). Specifically in macrophages, it has been shown that the genesis of new lipid bodies can be evoked by a variety of inflammation-related stimuli, including oxidized low-density lipoprotein (oxLDL) and oxLDL-components (but not native LDL) acting through membrane and nuclear receptors (9–12). Pathogens including Gram-positive (Mycobacterium bovis bacillus Calmette-Guérin) and Gram-negative bacteria (Escherchia coli) (13–16), Chlamydia pneumoniae (17) and Trypanosoma cruzi (18), as well as pathogen-related molecules (LPS and lipoarabinomannan) (13, 14) acting through their specific receptors (CD14, TLR4, and TLR2) (13, 14) were also shown to elicit signaling that culminates with activation of ER-assembling lipid body machinery. Downstream to the activation by pathogen-derived molecules, endogenous molecules—yet to be characterized—may also trigger lipid body biogenesis during infection-driven inflammation therefore comprising potential therapeutic targets for lipid body regulated pathologies.

MCP-1 is the prototype of CC chemokines β subfamily and exhibits the most potent chemotactic activity for monocytes. Collectively, both experimental and clinical studies have clearly established a key role of MCP-1 in the pathogenesis of macrophage-driven inflammatory disturbances, such as atherosclerosis and sepsis (reviewed in Ref. 19). Beyond its conventional role in leukocyte recruitment, MCP-1 and its receptor CCR2 contributions to cell activation and inflammatory mediator production are beginning to be unveiled. The current study shows that MCP-1 directly activates the biogenesis of lipid bodies equipped with active leukotriene B4 (LTB4)-synthesizing machinery within macrophages. MCP-1-induced lipid body formation and function signals through MCP-1 receptor CCR2 and the ERK and PI3K. Moreover, we demonstrated that MCP-1-driven lipid body biogenesis is a highly regulated phenomenon that culminates in microtubule-dependent lipid body assembly and protein compartmentalization leading to enhanced LTB4-synthesizing lipid bodies during inflammatory response such as the observed during sepsis or endotoxia.

Materials and Methods

Animals

The C3H/HeJ, LPS hyporesponsive mouse strain that has an inactivating point mutation within the signal transducing domain of the Tlr4 gene (20), and the LPS-responsive mouse strain C3H/He of both sexes weighing 20–25 g were obtained from the Fundação Oswaldo Cruz Breeding Unit. MCP-1-deficient mice (MCP-1−/−) of C57BL/6 genetic background and wild-type litter mates (21) were provided from Dr. C. Gerard (Harvard Medical School, Boston, MA) and CCR2-deficient mice (CCR2−/−) (22) were provided by Dr. W. Kuziel (PDL BioPharma, Fremont, CA) and bred at the Departamento de Fisiologia e Farmacodinâmica (Fundação Oswaldo Cruz, Rio de Janeiro, Brazil) experimental animal facility. Animals were caged with free access to food and fresh water in a room at 22–24°C and a 12-h light-dark cycle. Animal protocols were in agreement to the animal care guidelines of the National Institute of Health and were approved by the Oswaldo Cruz Animal Welfare Committee.

Mouse model of endotoxemia and sepsis: cecal ligation and puncture (CLP)

A murine model of endotoxemia and of polymicrobial sepsis was induced by CLP as previously described (16). Briefly, endotoxemia was induced in wild-type and MCP-1−/− mice with LPS (from E. coli 0111:B4; 300 µg/cavity i.p.) diluted in sterile saline. Control groups received equal volumes of vehicle. All endotoxin-stimulated animals appeared acutely ill and displayed signs of lethargy and diarrhea.

Poly microbial sepsis was induced in MCP-1−/− and wild-type mice anesthetized with a mixture of thiopental (40 mg/kg) and ketamine (80 mg/kg) diluted in sterile saline and administered i.p. (0.2 ml), as previously described (23). In brief, the cecum was punctured once with an 18-gauge needle and was then gently squeezed to empty its contents through the puncture. Immediately after the surgery, 0.5 ml of sterile saline was administered s.c. to the animals for volume resuscitation. Sham-treated mice were subjected to identical procedures except that ligation and puncture of the cecum were omitted. Animals subjected to CLP developed early signs of sepsis, including lethargy, piloerection, and diarrhea.

In vitro stimulation and treatment of macrophages

Peritoneal exudate cells removed from CCR2−/−, MCP-1−/− or C57BL/6 wild-type mice were cultured in RPMI 1640 medium with t-glutamine, sodium bicarbonate, 1% of antibiotic (10,000 U/ml penicillin and 10,000 µg/ml streptomycin), 0.5% FCS at 2 × 106 cells/ml on 24-well plates. Cells were pretreated with anti-MCP-1/CCL2 (10 µg/ml; R&D Systems). To study the effect of inhibitors, cells were pretreated with LY294002, PD98059, U0126 (1 or 10 µM), taxol or colchicine (0.1 or 1 µM) at 37°C for 30 min before the stimulation with MCP-1 (25, 50 or 100 nM; PepToTech) or LPS (500 ng/ml; from E. coli 0127:B8) for different time intervals at 37°C. The cell viability, determined by trypan blue dye exclusion at the end of each experiment, was >90% for each drug.

Lipid body analysis

Macrophages were stained with oil red O (Sigma-Aldrich) or osmium tetroxide (Electron Microscopy Science). In brief, macrophages were fixed in 3.7% formaldehyde in Ca2+- and Mg2+-free HBSS (pH 7.4) for 30 min. For oil red O staining, cells were rinsed in 85% propylene glycol, stained in 0.5% oil red O for 10 min, rinsed in 85% propylene glycol (5 min) and counterstained with hematoxylin for 30 s. For osmium staining, cells were rinsed in 0.1 M cacodylate buffer, 1.5% OsO4 (30 min), rinsed in dH2O, immersed in 1.0% thiorcarbohydroxide (5 min), rinsed in 0.1 M cacodylate buffer for 10 min, then rinsed in dH2O, dehydrated, and embedded in Epon. The morphology of fixed cells was observed, and lipid bodies were enumerated by light microscopy with a ×10 objective lens in 50 consecutively scanned macrophages.

LTB4 measurement

LTB4 were measured directly in the cell-free supernatants from peritoneal lavage obtained 6 h after vehicle, LPS, or CLP, or from in vitro-stimulated macrophages. In indicated experiments, vehicle, LPS, or MCP-1-1 in vitro-stimulated macrophages (6 h) were restimulated with A23187 (0.5 µM) for 15 min. Stimulatory reaction was stopped on ice, and the samples were centrifuged at 500 × g for 10 min at 4°C. The levels of LTB4 in cell supernatants were assayed by an enzyme immunoassay kit according to the manufacturer’s instructions (Cayman Chemical).

Intracellular immunodetection of newly synthesized LTB4 within macrophages

To immunodetect of newly formed LTB4 at its subcellular sites of synthesis within in vivo LPS-stimulated or in vitro MCP-1-stimulated macrophages, the cell preparations were mixed with 500 µl of water-soluble 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide (EDAC in HBSS; 0.5%; final concentration with cells; Sigma-Aldrich), used to cross-link eico-sanoïd carboxyl groups to amines in adjacent proteins. After 30–40 min incubation at 37°C with EDAC to promote both cell fixation and permeabilization, peritoneal macrophages were then washed with HBSS, cytospun onto glass slides, and blocked with HBSS containing 2% normal donkey serum for 10 min. The cells were then sequentially incubated with a rabbit anti-LTB4 antisem (Cayman Chemical) for 45 min. Then, a guinea pig anti-ADRP polyclonal Ab (Research Diagnostics) or Bodipy 493/503 (Molecular Probes) was added for 45 min to distinguish cytoplasmic lipid bodies within leukocytes. The cells were then washed with HBSS for 10 min (three times) and incubated with Cy2-labeled anti-rabbit IgG plus Cy3-labeled anti-guinea pig IgG secondary Abs for 1 h. The specificity of the LTB4 immunolabeling was ascertained by three different approaches: (1) a nonimmune rabbit IgG used as an irrelevant control to anti-LTB4 Ab; (2) incubation (30 min prior EDAC) with the inhibitor of 5-lipoxygenase (5-LO) zileuton (1 µM) to avoid the synthesis of LTB4; and (3) the analysis of LTB4 staining within nonstimulated leukocytes.
The images were obtained using an Olympus BX-F1A fluorescence microscope and CoolSNAP-Pro CF digital camera in conjunction with Image-Pro Plus version 4.5.1.3 software (MediaCybernetics). The images were analyzed using Adobe Photoshop 5.5 software (Adobe Systems).

**Immunodetection of microtubular system of macrophages**

Immunodetection of microtubular network of MCP-1-stimulated resident peritoneal macrophages of wild-type animals was performed by immunostaining α-tubulin. In brief, macrophages stimulated for 6 h with rm MCP-1 (100 nm) were fixed in 4% formaldehyde plus 4% sucrose (20 min) and permeabilized with ammonium chloride/PBS 50 nM (30 min) plus 0.05% saponin/PBS solution (30 min). After wash, macrophages were incubated for 1 h with mouse anti-α-tubulin mAbs diluted in 0.05% saponin plus 0.2% gelatin/PBS solution (overnight). After three washes with 0.05% saponin with 0.2% gelatin/PBS solution (10 min each), the preparations were incubated for 1 h with the Cy2-labeled anti-mouse IgG detection Ab (Jackson ImmunoResearch Laboratories) for 1 h. Slides were then washed three times, stained with 4’,6’-diamidino-2-phenylindole (0.5 μg/ml, 5 s; Molecular Probes), and washed with PBS and distilled water (10 min). To distinguish cytoplasmic lipid bodies within α-tubulin-labeled macrophages, anti-ADRP was added, as described above. Alternatively, α-tubulin-labeled cells were costained with anti-5-LO. Briefly, after fixation and permeabilization, slides were incubated for 1 h with anti-5-LO polyclonal Ab (Cayman Chemical) diluted in 0.05% saponin/BBSS solution. Non-immune rabbit serum was used as control. Immunodetection was achieved with a Cy3-labeled anti-guinea pig detection Ab (Jackson ImmunoResearch Laboratories). Cell images were obtained and analyzed as described above.

**Statistical analysis**

The data are represented as mean ± SEM and were statistically analyzed by means of ANOVA, followed by the Newman-Keuls-Student test, with a significance level set at \( p < 0.05 \).

**Results**

**Lipid body biogenesis and LTB\(_4\)-synthesizing function elicited by infection-driven inflammation are mediated by endogenous MCP-1**

A putative role of MCP-1 as an endogenous regulator of lipid body biogenesis and LTB\(_4\)-synthesizing function during infection-driven inflammation was investigated using two mouse models of peritonitis, polymicrobial infection sepsis induced by CLP (Fig. 1A) and LPS-induced endotoxemia (Fig. 1B), in MCP-1\(^{-/-}\) vs wild-type mice. As previously reported, the numbers of cytoplasmic lipid bodies found within peritoneal macrophages of wild-type animals undergoing either a septic condition or endotoxemia were markedly increased (13, 16, 24). As shown in Fig. 1, A and B, basal levels of lipid bodies were not altered within macrophages of MCP-1\(^{-/-}\) mice. In both experimental models, lipid body biogenesis was virtually absent in MCP-1\(^{-/-}\) mice (Fig. 1A, A and B), but very pronounced in the wild-type mice. Therefore, endogenous MCP-1 produced during sepsis- and/or endotoxin-driven inflammatory responses has a critical role on activation of lipid body assembling machinery within responsive macrophages. Of note, participation of endogenous MCP-1 in lipid body biogenesis depends on the stimulus. For instance, mycobacterial infection-induced lipid bodies in macrophages are MCP-1 independent (14).

In both experimental models of infection and concurring with sepsis- and endotoxin-induced in vivo lipid body biogenesis, the production of LTB\(_4\) was also prominent in wild-type animals, but negligible in MCP-1\(^{-/-}\) animals (Fig. 1A, A and B). This parallelism between reduced numbers of lipid bodies and levels of secreted LTB\(_4\) observed in MCP-1\(^{-/-}\) animals turned up to be a functional correlation. Intracellular compartments of LTB\(_4\) synthesis have never been determined. As illustrated in Fig. 1C, by using a new methodology that cross-linked and immunolabeled eicosanoids at its sites of synthesis (25), resident macrophages were identified as the cell population responsible for LTB\(_4\) production during endotoxin-induced inflammatory reaction. The specificity of the LTB\(_4\) immunolabeling was ascertained by the lack of LTB\(_4\) immunolabeling within zileuton pretreated LPS-stimulated macrophages or within nonstimulated macrophages (Fig. 1C).

A detailed analysis revealed that the intracellular LTB\(_4\)-synthesizing compartment was in a punctate cytoplasmic pattern, proximate to, but separate from the nucleus, and fully consistent in size and form with macrophage lipid bodies. In fact, the compartmentalization of newly formed LTB\(_4\) at macrophage lipid bodies was ascertained by the colocalization with ADRP (Fig. 1D). Virtually no LTB\(_4\) immunolabeling was observed within LPS-stimulated macrophages of MCP-1\(^{-/-}\) animals (Fig. 1D), thus showing that the newly formed lipid bodies of in vivo LPS-stimulated macrophages are inducible MCP-1-elicited organelles, which are enzymatically skilled for an effective LTB\(_4\) synthesis. LTB\(_4\)-synthesizing function of LTB\(_4\)-synthesizing function is within macrophages

To investigate whether MCP-1 was indeed capable of inducing formation of new lipid bodies, we have directly stimulated in vitro mouse macrophages with rm MCP-1. MCP-1 induced a dose-dependent increase in the numbers of cytoplasmic lipid bodies within resident peritoneal macrophages isolated from naive mice (Fig. 2A). As shown in Fig. 2B, rMCP-1-induced lipid body biogenesis was a rapid phenomenon, which was significant within 2 h and maximum within 6 h at the concentration of 100 nM. In parallel to the increased number of newly assembled lipid bodies (within 6 h), rMCP-1 (100 nM) also caused the release of LTB\(_4\) by macrophages (Fig. 2C). MCP-1-induced lipid body biogenesis and LTB\(_4\)-synthesizing function are not due to LPS contamination, because: 1) the neutralizing Ab against MCP-1 abolished MCP-1 effect (17.8 ± 0.9 lipid bodies per rMCP-1-stimulated cell vs 4.2 ± 0.1 lipid bodies found in anti-MCP-1-treated MCP-1-stimulated cell; \( n = 6 \)); and 2) the resident peritoneal macrophages isolated from TLR4-deficient mice respond to rMCP-1 (100 nM), but not to LPS, with rapid (6 h) lipid body biogenesis and LTB\(_4\) synthesis and similar magnitude to that observed with macrophages isolated from wild-type mice (Table I).

As shown in Fig. 2D, LTB\(_4\) was synthesized within the cytoplasmic lipid bodies found in MCP-1-stimulated macrophages, because immunofluorescent LTB\(_4\) was clearly compartmentalized within punctate bodipy labeled organelles. Therefore, MCP-1 induces the rapid formation of distinctive lipid bodies assembled with a specific protein composition that enable LTB\(_4\) synthesis by macrophages. Of note, eicosanoid-synthesizing function may vary according with leukocyte type and stimulatory condition, inasmuch as protein composition of newly formed lipid bodies can be heterogeneous.

**Cellular mechanisms of infection-related lipid body biogenesis and LTB\(_4\)-synthesizing function depend on an autocrine/paracrine activity of macrophage-derived MCP-1**

To further investigate the mechanisms of MCP-1-driven lipid body biogenesis and LTB\(_4\)-synthesizing function, macrophages stimulated in vitro with LPS were treated with a neutralizing Ab against MCP-1. The neutralization of MCP-1 inhibited both lipid body formation and LTB\(_4\) production (Table II), indicating that LPS-stimulated macrophages secrete MCP-1 acting autocrinally and/or paracrinically on macrophages triggers the assembling of LTB\(_4\)-synthesizing lipid bodies. Confirming the results with the neutralizing Ab to MCP-1, MCP-1\(^{-/-}\) mouse-derived resident macrophages stimulated in vitro with LPS displayed negligible lipid body biogenesis (Table II). The addition of exogenous MCP-1 to MCP-1\(^{-/-}\) macrophages was able to induce per se a significant increase in lipid body number (data not shown) as well as, to completely
FIGURE 1. MCP-1 mediates lipid body formation and LTB4 synthesis induced by infection-driven inflammatory response. In A and B, sepsis (CLP) and endotoxemia models of inflammation, respectively, were performed in wild-type vs MCP−/− mice. Analyses of lipid body formation and LTB4 production were performed 6 h after stimulation. Results were expressed as means ± SEM from at least eight animals; +, p ≤ 0.05 compared with wild-type control group; *, p ≤ 0.05 compared with wild-type stimulated-mice. In C, leukocytes from in vivo vehicle- (right panel) or LPS-stimulated animals (middle panel) were immunolabeled for newly formed LTB4 6 h after stimulation. LPS-stimulated animals were treated with zileuton (1 μM), 30 min before incubation with EDAC (left panel). Images show that LTB4 immunolabeling has a punctate cytoplasmic pattern that is absent in nonstimulated cells, inducible by LPS, and sensitive to zileuton. In D, anti-LTB4 was merged with identical field of anti-ADRP fluorescent images of macrophages recovered from wild-type (top panels) vs MCP−/− (bottom panels) mice stimulated with LPS. Images show LTB4 immunoreactive lipid bodies (as identified by anti-ADRP) of peritoneal macrophages. Scale bars, 5 μm.
MCP-1 induces lipid body biogenesis and LTB₄ synthesis within newly formed lipid bodies of in vitro-stimulated macrophages. Dose-response (A) and kinetic (B) curves of lipid body biogenesis triggered by direct in vitro stimulation of macrophages with MCP-1. In C, analysis of LTB₄ production was performed 6 h after MCP-1 (100 nM) stimulation. Results were expressed as means ± SEM from at least three different animals; +, p ≤ 0.05 and ++, p ≤ 0.01 compared with PBS-stimulated cells. In D, macrophages stimulated in vitro with PBS (top panels) or MCP-1 (100 nM; bottom panels) were stained with oil red O (left panels), bodipy (middle panels), or anti-LTB₄. Images show that newly formed lipid bodies (as identified by oil red O and bodipy labeling) are sites of LTB₄ synthesis within MCP-1-stimulated macrophages. Scale bars, 5 μm.

FIGURE 2. MCP-1 induces lipid body biogenesis and LTB₄ synthesis within newly formed lipid bodies of in vitro-stimulated macrophages. Dose-response (A) and kinetic (B) curves of lipid body biogenesis triggered by direct in vitro stimulation of macrophages with MCP-1. In C, analysis of LTB₄ production was performed 6 h after MCP-1 (100 nM) stimulation. Results were expressed as means ± SEM from at least three different animals; +, p ≤ 0.05 and ++, p ≤ 0.01 compared with PBS-stimulated cells. In D, macrophages stimulated in vitro with PBS (top panels) or MCP-1 (100 nM; bottom panels) were stained with oil red O (left panels), bodipy (middle panels), or anti-LTB₄. Images show that newly formed lipid bodies (as identified by oil red O and bodipy labeling) are sites of LTB₄ synthesis within MCP-1-stimulated macrophages. Scale bars, 5 μm.

restored the reduced LPS-induced biogenesis of LTB₄-synthesizing lipid bodies observed within MCP-1+/− macrophages (Table II). Therefore, MCP-1+/− mice express functional MCP-1 receptors on macrophages capable of eliciting lipid body biogenesis and compartmentalized LTB₄ synthesis. Altogether, these findings indicate that macrophages facing infection-related stimulatory conditions will respond initially secreting MCP-1, which in an autocrine/paracrine fashion may activate receptors expressed on the extracellular surface of macrophages.

Table I. In vitro direct effects of rMCP-1 on lipid body biogenesis and LTB₄ synthesis are not due LPS contamination, because activation of TLR4 is not involved in these phenomena

<table>
<thead>
<tr>
<th>Condition</th>
<th>Animal Strain</th>
<th>Lipid Bodies/Cell</th>
<th>LTB₄ (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>C3H/He</td>
<td>2.45 ± 0.09</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>rMCP-1</td>
<td>C3H/He</td>
<td>9.30 ± 0.17</td>
<td>0.73 ± 0.27</td>
</tr>
<tr>
<td>PBS</td>
<td>C3H/He</td>
<td>3.71 ± 0.09</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>LPS</td>
<td>C3H/He</td>
<td>9.26 ± 0.09</td>
<td>0.42 ± 0.10</td>
</tr>
<tr>
<td>PBS</td>
<td>C3H/HeJ</td>
<td>3.87 ± 0.08</td>
<td>0.06 ± 0.00</td>
</tr>
<tr>
<td>rMCP-1</td>
<td>C3H/HeJ</td>
<td>9.64 ± 0.19</td>
<td>0.55 ± 0.17</td>
</tr>
<tr>
<td>PBS</td>
<td>C3H/HeJ</td>
<td>4.32 ± 0.09</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>LPS</td>
<td>C3H/HeJ</td>
<td>4.56 ± 0.10</td>
<td>0.01 ± 0.00</td>
</tr>
</tbody>
</table>

a Macrophages isolated from TLR4-sensitive (C3H/He) and nonsensitive (C3H/HeJ) mice were stimulated in vitro with rMCP-1 (100 nM) or PBS (500 ng/ml) for 6 h. In vitro PBS, rMCP-1- or LPS-stimulated macrophages were restimulated with A23187 (0.5 μM) for 15 min prior to LTB₄ analysis. Results were expressed as means ± SEM from at least three distinct animals.

b Value of p ≤ 0.05 compared to proper PBS-stimulated cells.

Table II. Autocrine/paracrine effect of endogenous MCP-1 secreted by LPS-stimulated macrophages in vitro

<table>
<thead>
<tr>
<th>Condition</th>
<th>Animal Strain</th>
<th>Lipid Bodies/Cell</th>
<th>LTB₄ (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>C3H/He</td>
<td>9.64 ± 0.19</td>
<td>0.55 ± 0.17</td>
</tr>
<tr>
<td>LPS</td>
<td>C3H/HeJ</td>
<td>4.32 ± 0.09</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>rMCP-1</td>
<td>C3H/HeJ</td>
<td>4.56 ± 0.10</td>
<td>0.01 ± 0.00</td>
</tr>
</tbody>
</table>

a Macrophages isolated from wild-type and MCP-1+/− mice were stimulated in vitro with LPS alone or costimulated with rMCP-1 (100 nM) for 6 h. Pretreatment with neutralizing Ab anti-MCP-1 was performed 30 min before stimulation. Vehicle, LPS, or rMCP-1 in vitro-stimulated macrophages (6 h) were restimulated with A23187 (0.5 μM) for 15 min prior to LTB₄ analysis. Results were expressed as means ± SEM from at least three distinct animals.

b Value of p ≤ 0.05 compared to PBS-stimulated cells.

c Value of p ≤ 0.05 compared to LPS-stimulated cells isolated from wild-type mice.

d Value of p ≤ 0.05 compared to LPS-stimulated cells isolated from MCP-1+/− mice.

Molecular mechanisms involved in MCP-1-driven assembling of LTB₄-synthesizing lipid bodies depend on CCR2, ERK, and PI3K activation

New lipid bodies assembled in ER membranes are not a simply sign of injury or excess lipid substrate. In fact, the biogenic process of lipid bodies is a complex cellular outcome triggered in a stimuluss- and cell-dependent fashion by a variety of distinct signaling pathways. Here, our attempts to characterize the molecular signals committed to MCP-1-induced biogenesis of LTB₄-synthesizing lipid bodies revealed that CCR2 receptors and downstream signaling through ERK and PI3K are involved. As illustrated in Fig. 3, resident macrophages isolated from the MCP-1 receptor CCR2−/− mice were not able to assemble new lipid bodies in response to in vitro stimulation with LPS or rMCP-1. Moreover, two inhibitors of ERK 1/2 (PD98059 and U0126), even though did not alter the basal numbers of lipid bodies found in nonstimulated macrophages (data not shown), inhibited in a dose-dependent manner the MCP-1-induced lipid body biogenesis and the concurrent LTB₄ production (Fig. 4A). Similarly, an inhibitor of PI3K (LY294002) also blocked both formation and LTB₄-synthesizing function of lipid bodies induced by rMCP-1 (Fig. 4B). Collectively, our findings indicate that CCR2-elicited intracellular signaling cascade, characterized by ERK 1/2 and PI3K activation, switches on biogenesis of lipid bodies, particularly equipped with active LTB₄-synthesizing machinery. Of note, ERK and PI3K activation are known to be

FIGURE 3. MCP-1 induces lipid body formation and LTB₄ synthesis in macrophages through CCR2 activation. In vitro stimulation with LPS (A) or MCP-1 (B) trigger formation of new lipid bodies within macrophages isolated from wild-type, but not from CCR2−/−, animals. Analysis of lipid body formation was performed 6 h after in vitro stimulation. Results were expressed as the means ± SEM from at least three different animals; +, p ≤ 0.05 compared to wild-type control group; *, p ≤ 0.05 compared with wild-type stimulated mice.

FIGURE 4. Autocrine/paracrine effect of endogenous MCP-1 secreted by LPS-stimulated macrophages in vitro
Microtubule dynamics controls MCP-1-induced assembling of LTB₄-synthesizing lipid bodies

Microtubules play a well-demonstrated role in the cytoplasmic transport and spatial distribution of organelles; however, microtubular function on organelle biogenesis is not well-defined (28). Here, to study a putative role of microtubules on lipid body biogenesis and function, microtubule-active drugs were used. To understand the effect of microtubule depolymerization, peritoneal resident macrophages were pretreated with colchicine, a microtubule-destabilizing drug. Colchicine inhibited in a dose-dependent manner the assembling of new lipid bodies and synthesis of LTB₄ induced in vitro by LPS (Figs. 5A and 6A) or rMCP-1 (Figs. 5B and 6B). Therefore, disassembly of microtubules may disrupt ER biogenic machinery of LTB₄-synthesizing lipid bodies that may be in part dependent on the maintenance of a well-organized microtubule network. To further evaluate the effect of sustained microtubular polymerization, peritoneal resident macrophages were pretreated with taxol, a microtubule-stabilizing drug. As colchicine, taxol inhibited in a dose-dependent manner the assembling of new lipid bodies and synthesis of LTB₄ induced in vitro by LPS (Figs. 5A and 6A) or rMCP-1 (Figs. 5B and 6B). In as much as both microtubule disrupting vs stabilizing drugs (colchicine and taxol, respectively) have inhibitory effects on lipid body biogenesis and LTB₄-synthesizing function, we conclude that MCP-1-elicited highly regulated assembly of a lipid body depends on microtubule dynamics.

The inhibitory effect on biogenesis of LTB₄-synthesizing lipid bodies observed in the presence of taxol was accompanied by rearrangement of microtubule distributions, as visualized in MCP-1-stimulated peritoneal resident macrophages labeled with immunofluorescent α-tubulin. As illustrated in Figs. 5C and 6C, the microtubular system of MCP-1-stimulated macrophages appears as a delicate network that radiates from the nucleus. Enmeshed in this microtubule network, immunolabeled ADRP-positive lipid bodies appeared as peripheral circumferential staining found either adjacent to or distant from the nucleus within macrophage cytoplasm (Fig. 5C), suggestive of MCP-1-induced motility of newly assembled lipid body on microtubule tracks. As ADRP is a key regulator of lipid body biogenesis, 5-lipoxygenase (5-LO) is a limiting step of the LTB₄-synthesizing pathway. As shown in Fig. 6C, differently from external ring-like ADRP immunostaining, confirming previous ultrastructural data suggesting that 5-LO pervades the lipid body core (29). Both lipid body relevant biogenic and functional proteins were affected by taxol-induced microtubule stabilization. As shown in the bottom images of Figs. 5C and 6C, pretreatment with taxol for 30 min reorganizes the MCP-1-induced microtubule orientation in a typical peripheralization of microtubule bundles and impairs the formation of ADRP-circumscribed lipid bodies at the immunofluorescence levels. Therefore, active microtubule derangement seems to represent one of the molecular events involved in the activation of ADRP-regulated biogenic machinery and 5-LO-driven...
MCP-1-elicited LTB₄ production was analyzed 6 h after stimulation. Re-}taxol and colchicine, 30 min before MCP-1 treatment. Active drugs, including taxol and colchicine, disrupt lipid body biogenesis, indicating a requisite role for CCR2 in lipid body assembly. It is noteworthy that besides inducing chemotactic activity, chemokine receptors can evoke leukocyte activation characterized by enhanced biogenesis of lipid bodies. For instance, activation of the eicosanophilic receptor CCR3 by eotaxin (CCL11), eotaxin-2 (CCL24), eotaxin-3 (CCL26), or RANTES (CCL5) stimulates lipid body biogenesis in eosinophils (25, 30, 31). Our findings indicate that CCR2-driven lipid body biogenesis triggered by MCP-1 is dependent on downstream activation of PI3K and ERK1/2 kinases. Accordingly, activation of ERK 1/2 and PI3K in response to CC chemokines has been shown to participate in the regulated activation of lipid body biogenesis in other cell systems (25, 32), as well as in other MCP-1-induced leukocyte functions (26, 33). The specific isoform(s) involved in MCP-1-induced lipid body biogenesis are presently unknown. In addition to controlling lipid body biogenesis, activation of kinases within lipid bodies may have impacts to lipid body functions and interactions with organelles and cytoskeleton. In fact, Yu et al. (34, 35) demonstrated that PI3K regulatory and catalytic subunits, as well as ERK1, ERK2, and p38 MAPK, are compartmentalized and active within macrophage lipid bodies, suggesting that kinase-mediated signaling may take place within cytoplasmic lipid bodies in leukocytes.

Besides signaling molecules, structural molecules may also participate in downstream activation of lipid body biogenic machinery in macrophage ER. In fact, one can speculate that the role of MAPK and PI3K in lipid body biogenesis is presumably to provide activation of structural proteins actually involved in assembling lipid bodies. Recent studies using NIH 3T3 cells stimulated with insulin have established that dynein, a microtubule motor, has a central role in the growth of lipid bodies by fusing them (36). Dynein required phosphorylation, performed by the MAPK ERK2, to interact with its cargos, such as lipid bodies and may potentially control lipid body assembly by providing the structural conditions required to let the lipid body arise from the ER membrane (32). In agreement with this hypothesis, here we showed that lipid body assembly triggered by activation of CCR2 by MCP-1 depends on activities of both ERK 1/2 kinases and the microtubular system of macrophages.

It is well-established that microtubules have roles in cellular processes affecting lipid body size and location, such as lipid body growth (36) and motility (37). However, to best of our knowledge, no function of microtubules had been described on assembly of new lipid bodies. We hypothesized that a link between the source of the biogenic signal at cell membrane (e.g., CCR2 activation by MCP-1) and the ER-assembling machinery may involve cytoskeletal filaments, inasmuch as nascent lipid bodies are typically found emmeshed in them (38–40). To directly assess microtubular function, we have used a pharmacological approach by pretreating MCP-1-stimulated macrophages with microtubule-active drugs. Both microtubule disrupting vs stabilizing drugs (colchicine and taxol, respectively) blocked lipid body biogenesis, indicating that MCP-1-elicited ER lipid body assembly depends on activity of microtubule network. Whether the mechanism involved in microtubule-driven formation of lipid bodies depends on either a

**FIGURE 6.** MCP-1-induced LTB₄-synthesizing function of newly formed lipid bodies depends on microtubular dynamics within macrophages. To assess microtubule role on lipid body function as active compartment of LTB₄ synthesis, macrophages were pretreated with microtubule-active drugs, including taxol and colchicine, 30 min before MCP-1 (100 nM) stimulation. Concentrations of drugs were indicated in A and B, and taxol concentration in C was 1 µM. Respectively in A and B, LPS- and MCP-1-elicited LTB₄ production was analyzed 6 h after stimulation. Results were expressed as means ± SEM from at least three different animals; +, p ≤ 0.05 compared with control groups; *, p ≤ 0.05 and **, p ≤ 0.01 compared with LPS- or MCP-1-stimulated cells. In C, macrophages stimulated in vitro with MCP-1 for 6 h were stained with anti-tubulin (left panels) and anti-5-LO (middle panels). Right panels, Merged images illustrating the distribution of 5-LO-containing lipid bodies emmeshed in microtubule network of MCP-1-stimulated macrophages. Scale bars, 5 µm.

**Discussion**

Biogenesis of lipid bodies is a central event to whole body energy homeostasis, as well as to several important human diseases. In inflammatory reactions, leukocytes constantly show increased numbers of cytoplasmic lipid bodies. Advances on the mechanisms behind the enhanced biogenesis of leukocyte lipid bodies are of paramount importance for understanding the pathogenesis of inflammatory diseases, such as allergic, atherosclerotic, and infection-driven disorders. Here, focusing on macrophage-driven pathologies, we have unveiled MCP-1 as an endogenous and potent biogenic stimulus of enzymatically active lipid bodies, and placed MCP-1-elicited lipid body biogenic process was dependent on activation of a CCR2-elicited ERK and PI3K signaling, as well as, on an intact and dynamic microtubular system.

MCP-1 is a major mediator of leukocyte trafficking into the sites of the immune response. Here, the chemokine MCP-1 (CCL2) was identified as a molecule capable of initiate lipid body biogenesis in macrophages. How does a professional chemotaxtractant arrange an effective signaling to activate the lipid body biogenic machinery within macrophages? The activating mechanisms involved in MCP-1-induced lipid body formation within macrophages were analyzed. Cells that respond to MCP-1 stimulation with a chemotactic activity do so through activation of CCR2. MCP-1-induced macrophage lipid body formation was drastically inhibited in CCR2-deficient mice, indicating a requisite role for CCR2 in lipid body assembly. It is noteworthy that besides inducing chemotactic functions, chemokine receptors can evoke leukocyte activation characterized by enhanced biogenesis of lipid bodies. For instance, activation of the eicosanophilic receptor CCR3 by eotaxin (CCL11), eotaxin-2 (CCL24), eotaxin-3 (CCL26), or RANTES (CCL5) stimulates lipid body biogenesis in eosinophils (25, 30, 31). Our findings indicate that CCR2-driven lipid body biogenesis triggered by MCP-1 is dependent on downstream activation of PI3K and ERK1/2 kinases. Accordingly, activation of ERK 1/2 and PI3K in response to CC chemokines has been shown to participate in the regulated activation of lipid body biogenesis in other cell systems (25, 32), as well as in other MCP-1-induced leukocyte functions (26, 33). The specific isoform(s) involved in MCP-1-induced lipid body biogenesis are presently unknown. In addition to controlling lipid body biogenesis, activation of kinases within lipid bodies may have impacts to lipid body functions and interactions with organelles and cytoskeleton. In fact, Yu et al. (34, 35) demonstrated that PI3K regulatory and catalytic subunits, as well as ERK1, ERK2, and p38 MAPK, are compartmentalized and active within macrophage lipid bodies, suggesting that kinase-mediated signaling may take place within cytoplasmic lipid bodies in leukocytes.

Besides signaling molecules, structural molecules may also participate in downstream activation of lipid body biogenic machinery in macrophage ER. In fact, one can speculate that the role of MAPK and PI3K in lipid body biogenesis is presumably to provide activation of structural proteins actually involved in assembling lipid bodies. Recent studies using NIH 3T3 cells stimulated with insulin have established that dynein, a microtubule motor, has a central role in the growth of lipid bodies by fusing them (36). Dynein required phosphorylation, performed by the MAPK ERK2, to interact with its cargos, such as lipid bodies and may potentially control lipid body assembly by providing the structural conditions required to let the lipid body arise from the ER membrane (32). In agreement with this hypothesis, here we showed that lipid body assembly triggered by activation of CCR2 by MCP-1 depends on activities of both ERK 1/2 kinases and the microtubular system of macrophages.

**FIGURE 6.** MCP-1-induced LTB₄-synthesizing function of newly formed lipid bodies depends on microtubular dynamics within macrophages. To assess microtubule role on lipid body function as active compartment of LTB₄ synthesis, macrophages were pretreated with microtubule-active drugs, including taxol and colchicine, 30 min before MCP-1 (100 nM) stimulation. Concentrations of drugs were indicated in A and B, and taxol concentration in C was 1 µM. Respectively in A and B, LPS- and MCP-1-elicited LTB₄ production was analyzed 6 h after stimulation. Results were expressed as means ± SEM from at least three different animals; +, p ≤ 0.05 compared with control groups; *, p ≤ 0.05 and **, p ≤ 0.01 compared with LPS- or MCP-1-stimulated cells. In C, macrophages stimulated in vitro with MCP-1 for 6 h were stained with anti-tubulin (left panels) and anti-5-LO (middle panels). Right panels, Merged images illustrating the distribution of 5-LO-containing lipid bodies emmeshed in microtubule network of MCP-1-stimulated macrophages. Scale bars, 5 µm.
function as scaffold to the ER-assembling machinery (42) or an organelle involved in amplification of the inflammatory response, such as PI3K and dynein, needs to be established. Alternatively, inhibition of lipid body biogenesis may provide targets for anti-inflammatory therapy.

Acknowledgments

We are indebted to Dr. W. Kuziel (PDL BioPharma, Fremont, CA) and Dr. C. Benjamim (Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil) for kindly providing the CCR2-deficient mice used in this study. We thank Dr. Barret J. Rollins (Dana-Farber Cancer Institute, Boston, MA) and Dr. Craig Gerard (Children’s Hospital, Harvard Medical School, Boston, MA) for kindly providing MCP-1-deficient mice.

Disclosures

The authors have no financial conflict of interest.

References


